Cardiac Toxicity on NSABP B-31  
   
  1. Cardiac Toxicity on NSABP B-31
  2. B-31 Cardiac Monitoring Program Development Group
  3. B-31 Cardiac Monitoring Program Data Management
  4. NSABP B-31
  5. B-31 Design Assumptions
  6. B-31 Cardiac Eligibility Criteria
  7. B-31 LVEF Evaluation Schedule
  8. NSABP B-31 - Criteria for Trastuzumab Initiation
  9. B-31 Cardiac Event Primary Endpoint for Cardiac Safety
  10. Symptomatic Patients Real Time Blinded Evaluation
  11. NSABP B-31 - Cardiac Event Rates
  12. Trastuzumab Associated CHF Risk Factors
  13. Recovery of Patients Reporting Symptoms of Possible CHF
  14. Histograms of Left Ventricular Ejection Fraction
  15. B-31 LVEF Evaluation Schedule
  16. Asymptomatic Patients Criteria for Continuing Trastuzumab
  17. NSABP B-31 Trastuzumab Discontinuation Due to Asymptomatic or Symptomatic Cardiac Dysfunction by Quarter

Charles E Geyer Jr, MD